These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29614715)

  • 21. Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.
    Kovaleva M; Ferguson L; Steven J; Porter A; Barelle C
    Expert Opin Biol Ther; 2014 Oct; 14(10):1527-39. PubMed ID: 25090369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progress in shark single-domain antibody].
    Liu X; Chen Q
    Sheng Wu Gong Cheng Xue Bao; 2020 Jun; 36(6):1069-1082. PubMed ID: 32597058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry.
    Häsler J; Flajnik MF; Williams G; Walsh FS; Rutkowski JL
    Mol Immunol; 2016 Jul; 75():28-37. PubMed ID: 27213814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of Histidine-Enriched Shark IgNAR Variable Domain Antibody Libraries for the Isolation of pH-Sensitive vNAR Fragments.
    Könning D; Hinz S; Grzeschik J; Schröter C; Krah S; Zielonka S; Kolmar H
    Methods Mol Biol; 2018; 1827():109-127. PubMed ID: 30196494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ancient species offers contemporary therapeutics: an update on shark V
    English H; Hong J; Ho M
    Antib Ther; 2020 Jan; 3(1):1-9. PubMed ID: 32118195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoantibodies for detection and blocking of bioactivity of human vascular endothelial growth factor A(165).
    Tillib SV; Ivanova TI; Lyssuk EY; Larin SS; Kibardin AV; Korobko EV; Vikhreva PN; Gnuchev NV; Georgiev GP; Korobko IV
    Biochemistry (Mosc); 2012 Jun; 77(6):659-65. PubMed ID: 22817466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation of a pH-Sensitive IgNAR Variable Domain from a Yeast-Displayed, Histidine-Doped Master Library.
    Könning D; Zielonka S; Sellmann C; Schröter C; Grzeschik J; Becker S; Kolmar H
    Mar Biotechnol (NY); 2016 Apr; 18(2):161-7. PubMed ID: 26838965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation and characterization of malaria PfHRP2 specific V
    Leow CH; Fischer K; Leow CY; Braet K; Cheng Q; McCarthy J
    Malar J; 2018 Oct; 17(1):383. PubMed ID: 30355309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenesis effects of endostatin in retinal neovascularization.
    Bai YJ; Huang LZ; Zhou AY; Zhao M; Yu WZ; Li XX
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):619-26. PubMed ID: 23545016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles.
    Fernández-Quintero ML; Fischer AM; Kokot J; Waibl F; Seidler CA; Liedl KR
    Front Immunol; 2022; 13():953917. PubMed ID: 36177031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis.
    You JJ; Yang CH; Huang JS; Chen MS; Yang CM
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5290-8. PubMed ID: 17962485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural insights and biomedical potential of IgNAR scaffolds from sharks.
    Zielonka S; Empting M; Grzeschik J; Könning D; Barelle CJ; Kolmar H
    MAbs; 2015; 7(1):15-25. PubMed ID: 25523873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery.
    Li Z; Van Bergen T; Van de Veire S; Van de Vel I; Moreau H; Dewerchin M; Maudgal PC; Zeyen T; Spileers W; Moons L; Stalmans I
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5217-25. PubMed ID: 19474408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment.
    Burciaga-Flores M; Márquez-Aguirre AL; Dueñas S; Gasperin-Bulbarela J; Licea-Navarro AF; Camacho-Villegas TA
    Sci Rep; 2023 Mar; 13(1):3596. PubMed ID: 36869086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
    Ottiger M; Thiel MA; Feige U; Lichtlen P; Urech DM
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of Semi-Synthetic Shark IgNAR Single-Domain Antibody Libraries.
    Grzeschik J; Könning D; Hinz SC; Krah S; Schröter C; Empting M; Kolmar H; Zielonka S
    Methods Mol Biol; 2018; 1701():147-167. PubMed ID: 29116504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
    Edelman JL; Lutz D; Castro MR
    Exp Eye Res; 2005 Feb; 80(2):249-58. PubMed ID: 15670803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models.
    Jhanji V; Liu H; Law K; Lee VY; Huang SF; Pang CP; Yam GH
    Br J Ophthalmol; 2011 Sep; 95(9):1309-15. PubMed ID: 21719569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview and discovery of IgNARs and generation of VNARs.
    Nuttall SD
    Methods Mol Biol; 2012; 911():27-36. PubMed ID: 22886244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.